Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 7118 matches for

Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, aims to have vaccinated all 72 healthy adult volunteers by the end of January.

HRH The Duke of Gloucester Visits University of Oxford’s Cutting-Edge Vaccine Facilities

His Royal Highness the Duke of Gloucester visited the University of Oxford on Thursday 24th July to tour two of its leading medical research centres: the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI), located on the University’s Old Road Campus.

New jab protects babies from serious lung infection, study shows

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.

Construction begins on state-of-the-art research facility

The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford’s mission to counter and constrain global health threats.

Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time

The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.

Professor Simon Draper elected Fellow of the Academy of Medical Sciences

Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics and Kavli Institute for Nanoscience Discovery, has been elected as a Fellow to the Academy of Medical Sciences, it has been announced today.

New MenB Vaccine Shows Promise in Early-Stage Trial Results

The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.

Study identifies key immune structures in the gut that may drive coeliac disease

Researchers in Oxford have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease and could provide a target for future therapies.

Study shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children

Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.

Spotlight on Magdalen College Chapel for Rare Disease Day

The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.

New partnership to advance public health and life science research collaboration in West Africa

The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.

New study shows that early support for children living in marginalised communities can improve their developmental outcomes

Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.

Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies

Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.

Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection

Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.

Dr. Nicky Whiffin awarded Balfour Lecture 2025

Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford’s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.

University of Oxford unveils new vaccine development partnership

Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.

Ineos Oxford Institute makes award to OVG project tackling antimicrobial resistance

The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.

David Cameron resumes role as chair of Advisory Council for Oxford-Harrington Rare Disease Centre (OHC)

Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.

Typhoid vaccine trial confirms sustained protection for older children

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.

New campaign launched to encourage vaccine uptake

Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation

A major art installation featuring dramatically upscaled bacteria, viruses and a parasite has been unveiled at Oxford University’s Museum of Natural History to celebrate 30 years of vaccine development by the Oxford Vaccine Group (OVG) which has tackled some of the world’s most deadly diseases.

Load More

Similar stories